Aurobindo Pharma faces over ₹155-cr. GST demand, penalty


Generic drugmaker Aurobindo Pharma has received order under the Central Goods and Services Tax Act, 2017, asking it to pay GST, interest and a penalty of more than ₹155 crore.

Additional Commissioner of Central Tax, Ranga Reddy GST Commissionerate, Hyderabad, passed the order for the period 2017-18 to 2021-22 demanding GST of ₹77,61,35,242 along with interest. Further, a penalty of ₹77,61,35,242 was imposed, Aurobindo Pharma said in a filing on Wednesday.

An amount of ₹23,71,71,782 paid under protest by the company and ITC of ₹8,78,23,385 reversed by the company were ordered for appropriation, it said.

The order was passed on the contention that the company received excess IGST refund; non-surrender of IGST on short realisation of export proceeds with respect of exports during July 1, 2017 to March 23, 2020 and non-reversal of ITC in terms of Rule 37 of CGST Rules. The company intends to file an appeal before the Appellate Authority, Aurobindo Pharma said.



Source link

  • Related Posts

    Lupin, China’s SUP ink pact for COPD drug Tiotropium DPI

    Lupin has signed a license and supply agreement with Sino Universal Pharmaceuticals (SUP) for commercialisation of chronic obstructive pulmonary disease drug Tiotropium Dry Powder Inhaler, 18 mcg/capsule, in the Chinese…

    Continue reading
    India to export 150 locomotives to Africa worth over ₹3,000 crore

    “These locomotives are fitted with Distributed Power Wireless Control System, or DPWCS, for synchronised operations and superior freight handling,” a Railways Ministry spokesperson said. Photo: https://www.wabteccorp.com/ India will supply 150…

    Continue reading

    Leave a Reply

    Your email address will not be published. Required fields are marked *